Recombinant HCoV-OC43 Spike His-tag Protein, CF

2 μg/lane of Recombinant HCoV-OC43 Spike His-tag Protein (Catalog # 10989-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at >150 kDa.

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant HCoV-OC43 Spike His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to agglutinate mouse red blood cells. The ED₅₀ for this effect is 0.10‑1.00 µg/mL.
• Source: Human embryonic kidney cell, HEK293-derived hcov-oc43 Spike protein
  Val15-Pro1297 (Arg754Ser, Arg757Ser), with a C-terminal 6-His tag
• Accession #: YP_009555241.1
• N-terminal Sequence: Val15
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 144 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: >150 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant HCoV-OC43 Spike His-tag Protein, CF

• 2019-nCoV S Protein
• 2019-nCoV Spike
• COVID-19 Spike
• E2
• Human coronavirus spike glycoprotein
• Peplomer protein
• S glycoprotein
• S Protein
• SARS-COV-2 S protein
• SARS-COV-2 Spike glycoprotein
• SARSCOV2 Spike protein
• SARS-CoV-2
• Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
• Spike glycoprotein
• Spike
• surface glycoprotein

Background

HCoV-OC43, a virus first isolated in 1960's that accounts for ~ 20% of the common cold, belongs to a family of viruses known as coronaviruses that are commonly comprised of a large plus-strand RNA genome and four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1, 2). Other well-known human coronaviruses include three viruses that cause relatively mild respiratory disease: HCoV-229E, HCoV-HKU1 and HCov-NL63, plus three viruses that cause the Severe Acute Respiratory Syndrome (SARS-CoV), the Middle East Respirator Syndrome (MERS-CoV), and the global pandemic Covid-19 (SARS-CoV2). While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication, and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (3, 4). The CoV-OC43 N protein is a ~50 kDa protein composed of two independent structural domains connected by a linker region. Both the N-terminal and the linker regions contain RNA binding domains, while the C-terminal region is responsible for the oligomerization of the N protein (5). The CoV‑OC43 N protein shares 64% amino acid sequence identity with CoV-HKU1 N protein. the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity. Cross activity of antibodies among different strains should be rigorously tested when designing serological diagnostic kits (6, 7).

1. St-Jean, J.R. et al. (2004) J. Virol. 78:8824.
2. Vabret, A. et al. (2003) Fr Clin Infect Dis. 36:985.
3. Chang, C.K. et al. (2006) J. Biomed. Sci. 13:59.
4. Hurst, K.R. et al. (2009) J. Virol. 83:7221.
5. Huang, C.Y. et al. (2009) Protein Sci. 18:2209.
6. Chan, K.H. et al. (2005) Clin Diagn Lab Immunol. 12:1317.
7. Mourez, T. et al. (2007) J. Virol Methods. 139:175.

Bioinformatics

• Uniprot:
  • YP_009555241.1()